ITGB8 has been reported to be overexpressed in various cancers, especially in lung cancer and lung AD cell lines (Xu and Wu, 2012) and has recently been found to be related to gefitinib and cisplatin resistance in cancer (Cui et al., 2018). Here, ITGB8 is linked to lung carcinoma.